A Phase 1 interventional study of Azilsartan medoxomil (TAK-491) and Azilsartan medoxomil (TAK-491) in Hypertension, sponsored by Takeda. Terminated at 8 sites in 2 countries. Open to participants aged 1 Year to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-25.
Sponsored by Takeda · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing azilsartan medoxomil in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. azilsartan medoxomil · Hypertension.
Among the 21 studies testing azilsartan medoxomil in Hypertension, this one is the 20th largest by enrollment, is one of 2 that started in 2010, is one of 2 in phase 1, and was the 16th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →1 of the 21 studies testing azilsartan medoxomil in Hypertension is open now, in 1 country. Recruiting first, the newest first:
Gedeon Richter Plc. · Sites in Russian Federation
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 1 Year to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2010.
This study's enrollment of 29 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 566 across the 21 interventional studies. Of the 20 that completed or were terminated, 20 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 3 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
44 studies in Hypertension by Takeda: none open now, none under way, none of them phase 3. Of 43 finished, 34 (79%) have results posted.
Among the 44 studies in Hypertension by Takeda, this one is the 27th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2010, is one of 2 in phase 1, and was the 22nd registered.
Takeda’s Hypertension studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing azilsartan medoxomil in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 44 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess the pharmacokinetics (PK) and safety of a single dose of azilsartan medoxomil in children with hypertension, and comparative PK in healthy adults.
Within the past 10 years, the incidence of high blood pressure (hypertension) in children and adolescents has increased all over the world. This increase is connected in part to a growing number of people who are overweight and do not eat right or exercise enough. In younger children though, high blood pressure is a common consequence of underlying diseases, such as renal diseases.
This study looked at a blood pressure medicine called TAK-491 (azilsartan medoxomil) to see how it works in children who have hypertension. Azilsartan medoxomil is a prodrug that converts into TAK-536 (azilsartan), a blood pressure lowering medicine that had not been tested in children.
To be eligible to take part in this study, children with a diagnosis of hypertension (primary or secondary) must have been between the ages of 1 year and 16 years old (up to their 17th birthday). Each child was given one dose of azilsartan medoxomil, followed by a number of blood tests and assessments within 24 hours after taking azilsartan medoxomil to see how the medication is working. Adults who do not have hypertension also took part in this study to provide comparison.
This study took place in 9 sites in the UK and USA. A total of 20 children with hypertension and 9 adults without hypertension participated in this study.
This study lasted about 43 days. This included a 28 day screening period, a 2 day treatment phase and a follow up period. Each participant taking part in this study may have been requested to remain in a hospital for one overnight stay during the course of the study. Each participant was contacted by telephone 6 days and 15 days after taking azilsartan medoxomil.
Takeda has decided to close Cohort 3 (participants between 1 and 6 years of age with hypertension) enrollment early and end this study with the agreement of both the US Food and Drug Administration (FDA) and the Pediatric Committee (PDCO) at the European Medicines Agency. Requests to the FDA and PDCO were submitted to close the study without completion of enrollment in Cohort 3 due to difficulty enrolling this particular patient population. Takeda proposed an alternative option to collect PK data in this age subset by utilizing PK modeling to determine the appropriate doses in children 1-5 years of age in lieu of completing Cohort 3. The FDA and PDCO agreed with this approach.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Pediatric Participants:
Must have a diagnosis of hypertension (SBP and/or DBP ≥95th percentile for age/gender/height).
For Healthy Adult Participants:
For All Participants:
Exclusion Criteria:
For Pediatric Participants:
For all participants:
Has taken or requires the use of any medications, supplements, or food products within the stated time periods, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Azilsartan medoxomil 80 mg, tablets, orally, one day only
Drug: Azilsartan medoxomil (TAK-491)
Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
Drug: Azilsartan medoxomil (TAK-491)
Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
Drug: Azilsartan medoxomil (TAK-491)
Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
Drug: Azilsartan medoxomil (TAK-491)
Azilsartan medoxomil 80 mg, tablets, orally, one day only
Also known as: TAK-491
Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
Also known as: TAK-491
Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
Also known as: TAK-491
Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
Also known as: TAK-491
Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536
AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\[0-tlqc\]).
Time frame: Day 1
Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536 Metabolite M-II.
AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\[0-tlqc\]).
Time frame: Day 1
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536
Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC(0-inf)=AUC(0-tlqc) + Clast/λz.
Time frame: Day 1
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536 Metabolite M-II
Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC(0-inf)=AUC(0-tlqc) + Clast/λz.
Time frame: Day 1
Maximum Observed Plasma Concentration (Cmax) for TAK-536
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
Time frame: Day 1
Maximum Observed Plasma Concentration (Cmax) for TAK-536 Metabolite M-II
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
Time frame: Day 1
Time to Reach Cmax (Tmax) for TAK-536
Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 1.
Time frame: Day 1
Time to Reach Cmax (Tmax) for TAK-536 Metabolite M-II
Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 1.
Time frame: Day 1
Terminal Elimination Half-life (T1/2) for TAK-536
Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.
Time frame: Day 1
Terminal Elimination Half-life (T1/2) for TAK-536 Metabolite M-II
Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.
Time frame: Day 1
Apparent Oral Clearance (CL/F) for TAK-536
CL/F is apparent clearance of the drug from the plasma, expressed in L/hr.
Time frame: Day 1
Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)
Time frame: Day 1
Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)
Time frame: Day 1
Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)
Fe=\[Ae(0-24)/dose\]×100 (molecular weight adjusted for metabolites.
Time frame: Day 1
Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)
Fe=\[Ae(0-24)/dose\]×100 (molecular weight adjusted for metabolites.
Time frame: Day 1
Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)
Renal clearance, calculated as CLr=Ae(0-24)/AUC(0-24).
Time frame: Day 1
Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)
Renal clearance, calculated as CLr=Ae(0-24)/AUC(0-24).
Time frame: Day 1
Participants took part in the study at 6 sites in the United States and 3 sites in the United Kingdom from 10 May 2010 to 10 July 2013.
| Milestone | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mg | Cohort 2: Children (≥6 to <12 Years Old) 20-60 mg | Cohort 3: Children (≥1 to <6 Years Old) |
|---|---|---|---|---|
| Started | 9 | 9 | 8 | 3 |
| Completed | 9 | 9 | 8 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\[0-tlqc\]).
| ng.hr/mL | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 60 mg | Cohort 1: Adolescents (≥12 to <17 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 60 mg | Cohort 2: Children (≥6 to <12 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 20 mg | Cohort 3: Children (≥1 to <6 Years Old) |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536 | 40613 ± 9609.6 | 23889 ± 5383.8 | 17423 ± 3559.7 | 16056 ± NA | 22556 ± 5792.6 | 18691 ± 5489.9 | 16963 ± 4948.4 |
AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\[0-tlqc\]).
| ng.hr/mL | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 60 mg | Cohort 1: Adolescents (≥12 to <17 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 60 mg | Cohort 2: Children (≥6 to <12 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 20 mg | Cohort 3: Children (≥1 to <6 Years Old) |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536 Metabolite M-II. | 11563 ± 3106.5 | 7409 ± 78.6 | 7428 ± 2120.7 | 7392 ± NA | 7929 ± 3502.6 | 9130 ± 1338.3 | 7285 ± 3626.0 |
Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC(0-inf)=AUC(0-tlqc) + Clast/λz.
| ng.hr/mL | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 60 mg | Cohort 1: Adolescents (≥12 to <17 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 60 mg | Cohort 2: Children (≥6 to <12 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 20 mg | Cohort 3: Children (≥1 to <6 Years Old) |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536 | 44820 ± 11680.7 | 26411 ± 6703.1 | 18686 ± 3720.4 | 16563 ± NA | 23792 ± 6157.0 | 19543 ± 6181.1 | 17771 ± 5263.1 |
Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC(0-inf)=AUC(0-tlqc) + Clast/λz.
| ng.hr/mL | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 60 mg | Cohort 1: Adolescents (≥12 to <17 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 60 mg | Cohort 2: Children (≥6 to <12 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 20 mg | Cohort 3: Children (≥1 to <6 Years Old) |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536 Metabolite M-II | 19188 ± 6766.0 | 10596 ± 1168.8 | 12532 ± 3905.3 | 8961 ± NA | 11387 ± 5440.7 | 14230 ± 3419.6 | 9477 ± 4659.6 |
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
| ng/mL | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 60 mg | Cohort 1: Adolescents (≥12 to <17 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 60 mg | Cohort 2: Children (≥6 to <12 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 20 mg | Cohort 3: Children (≥1 to <6 Years Old) |
|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) for TAK-536 | 5699 ± 1346.1 | 3245 ± 106.1 | 2512 ± 701.6 | 2810 ± NA | 3858 ± 1363.0 | 2960 ± 364.3 | 3320 ± 656.0 |
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
| ng/mL | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 60 mg | Cohort 1: Adolescents (≥12 to <17 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 60 mg | Cohort 2: Children (≥6 to <12 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 20 mg | Cohort 3: Children (≥1 to <6 Years Old) |
|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) for TAK-536 Metabolite M-II | 736 ± 241.6 | 480 ± 74.2 | 535 ± 200.2 | 514 ± NA | 561 ± 211.7 | 561 ± 40.3 | 488 ± 212.2 |
Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 1.
| hr | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 60 mg | Cohort 1: Adolescents (≥12 to <17 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 60 mg | Cohort 2: Children (≥6 to <12 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 20 mg | Cohort 3: Children (≥1 to <6 Years Old) |
|---|---|---|---|---|---|---|---|
| Time to Reach Cmax (Tmax) for TAK-536 | 2.00 ± 0.8819 | 2.01 ± 0.0118 | 2.00 ± 0.4082 | 2.00 ± NA | 2.00 ± 2.2043 | 2.00 ± 0.0096 | 1.00 ± 0.0000 |
Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 1.
| hr | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 60 mg | Cohort 1: Adolescents (≥12 to <17 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 60 mg | Cohort 2: Children (≥6 to <12 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 20 mg | Cohort 3: Children (≥1 to <6 Years Old) |
|---|---|---|---|---|---|---|---|
| Time to Reach Cmax (Tmax) for TAK-536 Metabolite M-II | 6.00 ± 1.4227 | 5.00 ± 1.4142 | 6.00 ± 0.8256 | 6.00 ± NA | 4.03 ± 1.9890 | 4.00 ± 2.3094 | 6.0 ± 0.0000 |
Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.
| hr | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 60 mg | Cohort 1: Adolescents (≥12 to <17 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 60 mg | Cohort 2: Children (≥6 to <12 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 20 mg | Cohort 3: Children (≥1 to <6 Years Old) |
|---|---|---|---|---|---|---|---|
| Terminal Elimination Half-life (T1/2) for TAK-536 | 7.35 ± 1.083 | 7.74 ± 0.621 | 5.76 ± 1.158 | 5.07 ± NA | 5.75 ± 0.760 | 5.37 ± 0.922 | 4.59 ± 1.627 |
Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.
| hr | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 60 mg | Cohort 1: Adolescents (≥12 to <17 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 60 mg | Cohort 2: Children (≥6 to <12 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 20 mg | Cohort 3: Children (≥1 to <6 Years Old) |
|---|---|---|---|---|---|---|---|
| Terminal Elimination Half-life (T1/2) for TAK-536 Metabolite M-II | 16.60 ± 6.870 | 12.78 ± 2.915 | 14.00 ± 2.414 | 8.50 ± NA | 11.56 ± 3.314 | 13.97 ± 2.983 | 10.35 ± 2.770 |
CL/F is apparent clearance of the drug from the plasma, expressed in L/hr.
| L/hr | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 60 mg | Cohort 1: Adolescents (≥12 to <17 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 60 mg | Cohort 2: Children (≥6 to <12 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 20 mg | Cohort 3: Children (≥1 to <6 Years Old) |
|---|---|---|---|---|---|---|---|
| Apparent Oral Clearance (CL/F) for TAK-536 | 1.52 ± 0.414 | 1.88 ± 0.477 | 1.78 ± 0.411 | 2.90 ± NA | 1.43 ± 0.427 | 0.87 ± 0.232 | 0.54 ± 0.134 |
| mg | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 60 mg | Cohort 1: Adolescents (≥12 to <17 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 60 mg | Cohort 2: Children (≥6 to <12 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 20 mg |
|---|---|---|---|---|---|---|
| Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536) | 10.65 ± 4.673 | 4.56 ± 1.029 | 2.89 ± 0.936 | 4.59 ± NA | 3.63 ± 2.125 | 1.27 ± 0.580 |
| mg | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 60 mg | Cohort 1: Adolescents (≥12 to <17 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 60 mg | Cohort 2: Children (≥6 to <12 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 20 mg |
|---|---|---|---|---|---|---|
| Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II) | 6.60 ± 5.149 | 2.93 ± 0.582 | 2.73 ± 1.528 | 4.43 ± NA | 2.77 ± 1.197 | 1.48 ± 0.284 |
Fe=\[Ae(0-24)/dose\]×100 (molecular weight adjusted for metabolites.
| percent | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 60 mg | Cohort 1: Adolescents (≥12 to <17 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 60 mg | Cohort 2: Children (≥6 to <12 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 20 mg |
|---|---|---|---|---|---|---|
| Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536) | 16.65 ± 7.302 | 9.50 ± 2.144 | 9.04 ± 2.925 | 9.57 ± NA | 11.36 ± 6.639 | 7.94 ± 3.622 |
Fe=\[Ae(0-24)/dose\]×100 (molecular weight adjusted for metabolites.
| percent | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 60 mg | Cohort 1: Adolescents (≥12 to <17 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 60 mg | Cohort 2: Children (≥6 to <12 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 20 mg |
|---|---|---|---|---|---|---|
| Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II) | 11.01 ± 8.581 | 6.55 ± 1.293 | 9.11 ± 5.094 | 9.85 ± NA | 9.22 ± 3.991 | 9.89 ± 1.896 |
Renal clearance, calculated as CLr=Ae(0-24)/AUC(0-24).
| L/hr | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 60 mg | Cohort 1: Adolescents (≥12 to <17 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 60 mg | Cohort 2: Children (≥6 to <12 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 20 mg |
|---|---|---|---|---|---|---|
| Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536) | 0.28 ± 0.130 | 0.22 ± 0.051 | 0.17 ± 0.077 | 0.29 ± NA | 0.15 ± 0.069 | 0.07 ± 0.011 |
Renal clearance, calculated as CLr=Ae(0-24)/AUC(0-24).
| L/hr | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 60 mg | Cohort 1: Adolescents (≥12 to <17 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 60 mg | Cohort 2: Children (≥6 to <12 Years Old) 40 mg | Cohort 2: Children (≥6 to <12 Years Old) 20 mg |
|---|---|---|---|---|---|---|
| Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II) | 0.55 ± 0.309 | 0.37 ± 0.084 | 0.34 ± 0.146 | 0.60 ± NA | 0.36 ± 0.099 | 0.16 ± 0.022 |
Collected over A treatment-emergent adverse event (TEAE) had an onset occurring after the first dose of study medication and within 14 days after the last dose of study medication or, if an SAE, within 30 days after last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Healthy Adults | — | 0/9 (0%) | 2/9 (22.2%) |
| Cohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mg | — | 0/9 (0%) | 5/9 (55.6%) |
| Cohort 2: Children (≥6 to <12 Years Old) 20-60 mg | — | 0/8 (0%) | 3/8 (37.5%) |
| Cohort 3: Children (≥1 to <6 Years Old) | — | 0/3 (0%) | 0/3 (0%) |
| Event | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mg | Cohort 2: Children (≥6 to <12 Years Old) 20-60 mg | Cohort 3: Children (≥1 to <6 Years Old) |
|---|---|---|---|---|
| Abdominal discomfortGastrointestinal disorders | 0/9 | 2/9 | 0/8 | 0/3 |
| HeadacheNervous system disorders | 0/9 | 2/9 | 1/8 | 0/3 |
| Infusion site painGeneral disorders | 0/9 | 0/9 | 1/8 | 0/3 |
| SinusitisInfections and infestations | 0/9 | 0/9 | 1/8 | 0/3 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/9 | 0/9 | 1/8 | 0/3 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/9 | 0/9 | 1/8 | 0/3 |
| Sinus bradycardiaCardiac disorders | 1/9 | 0/9 | 0/8 | 0/3 |
| Infected bitesInfections and infestations | 1/9 | 0/9 | 0/8 | 0/3 |
| DizzinessNervous system disorders | 0/9 | 1/9 | 0/8 | 0/3 |
| MigraineNervous system disorders | 0/9 | 1/9 | 0/8 | 0/3 |
| Age, Continuous(years) | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mg | Cohort 2: Children (≥6 to <12 Years Old) 20-60 mg | Cohort 3: Children (≥1 to <6 Years Old) | Total |
|---|---|---|---|---|---|
| Mean | 28.3 ± 7.78 | 14.2 ± 1.64 | 9.1 ± 2.10 | 4.7 ± 0.58 | 16.2 ± 9.81 |
| Sex: Female, Male(Participants) | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mg | Cohort 2: Children (≥6 to <12 Years Old) 20-60 mg | Cohort 3: Children (≥1 to <6 Years Old) | Total |
|---|---|---|---|---|---|
| Female | 2 | 2 | 5 | 2 | 11 |
| Male | 7 | 7 | 3 | 1 | 18 |
| Race/Ethnicity, Customized(participants) | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mg | Cohort 2: Children (≥6 to <12 Years Old) 20-60 mg | Cohort 3: Children (≥1 to <6 Years Old) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 0 | 1 | 0 | 5 |
| Not Hispanic or Latino | 5 | 7 | 5 | 3 | 20 |
| Not Reported | 0 | 2 | 2 | 0 | 4 |
| Race/Ethnicity, Customized(participants) | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mg | Cohort 2: Children (≥6 to <12 Years Old) 20-60 mg | Cohort 3: Children (≥1 to <6 Years Old) | Total |
|---|---|---|---|---|---|
| Asian | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 1 | 2 | 2 | 2 | 7 |
| White | 8 | 7 | 5 | 1 | 21 |
| Height(cm) | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mg | Cohort 2: Children (≥6 to <12 Years Old) 20-60 mg | Cohort 3: Children (≥1 to <6 Years Old) | Total |
|---|---|---|---|---|---|
| Mean | 172.6 ± 9.70 | 163.1 ± 11.72 | 138.6 ± 12.74 | 107.7 ± 11.06 | 153.6 ± 23.45 |
| Weight(kg) | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mg | Cohort 2: Children (≥6 to <12 Years Old) 20-60 mg | Cohort 3: Children (≥1 to <6 Years Old) | Total |
|---|---|---|---|---|---|
| Mean | 74.64 ± 11.207 | 71.71 ± 15.512 | 48.50 ± 22.523 | 18.30 ± 4.026 | 60.69 ± 23.859 |
| Body Mass Index (BMI)(kg/m^2) | Cohort 1: Healthy Adults | Cohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mg | Cohort 2: Children (≥6 to <12 Years Old) 20-60 mg | Cohort 3: Children (≥1 to <6 Years Old) | Total |
|---|---|---|---|---|---|
| Mean | 25.06 ± 3.345 | 27.22 ± 6.611 | 24.29 ± 8.327 | 15.67 ± 0.551 | 24.54 ± 6.625 |
The record gives a start of May 2010, a primary completion of Jul 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azilsartan medoxomil